Michele A. Anderson, Chief Development Officer at Braveheart Bio, Inc. (BRVE), bought 1,111 shares at $18.00 ($20K) on 2026-08-07, disclosed to the SEC on 2026-08-07.
Chief Development Officer Michele A. Anderson purchased 1,111 shares for $19,998 at $18.00, marking the largest insider purchase in the company's history. This significant buy signals confidence in the company's pipeline and recent market positioning following its IPO.
The stock is currently trading at $31.82, representing a 10.68% premium to its 52-week low of $28.75 and sitting at the 52-week high of $31.82.
1) Q3 earnings on 2026-11-05 (based on earnings.next_earnings_date); 2) Braveheart Bio (BRVE) Raised $382.5 Million In Its IPO on 2026-08-11 (based on recent_news_7d); 3) The company filed a large shelf registration for future capital raises following its IPO on 2026-08-11 (based on recent_news_7d).
Insider purchases are occurring at a price ($18.00) significantly below the current market price ($31.82), suggesting the stock may be overvalued relative to the insider's entry point.
Nothing distinguishes this filing.